|
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists.
|
30808988 |
2019 |
|
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Molecular testing determined that his t-NEPC tumor (but not his original adenocarcinoma) harbored complete copy number loss of BRCA2, as well as copy number loss of another HR gene - ataxia telangiectasia, mutated (ATM).
|
31565603 |
2019 |
|
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
In the present study, barbatolic acid was isolated from the acetone extract of Bryoria capillaris, and its anti-breast cancer and anti-angiogenic potential was investigated using human umbilical vein endothelial cells (HUVECs), human breast ductal carcinoma (T-47D) and cisplatin-resistant BRCA2-mutated human breast TNM stage IV adenocarcinoma (HCC1428) cells.
|
30155608 |
2018 |
|
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
A PCR-based assay was used to screen 439 ovarian, fallopian tube or extra-ovarian cancers comprised of serous, high grade endometrioid and mixed cell adenocarcinomas with serous components for specific BRCA1: C4446T and 2953delGTAinsC and BRCA2: 8765delAG, G6085T, 3398del5 and E3002K mutations.
|
25884701 |
2015 |
|
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Inherited mutations in the tumor suppressor BRCA2 are predisposed to pancreatic adenocarcinomas, which carry activating mutations in the KRAS oncogene in more than 95% of cases, as well as frequent TP53 inactivation.
|
21289082 |
2011 |
|
Adenocarcinoma
|
0.090 |
GeneticVariation
|
group |
LHGDN |
A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature.
|
18036394 |
2007 |
|
Adenocarcinoma
|
0.090 |
PosttranslationalModification
|
group |
LHGDN |
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer.
|
17289874 |
2007 |
|
Adenocarcinoma
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung.No methylation of BRCA2 was detected.
|
14647419 |
2004 |
|
Adenocarcinoma
|
0.090 |
Biomarker
|
group |
BEFREE |
This human inducible NOS possessed consensus recognition sites for the cofactors FMN, FAD, and NADPH and calmodulin recognition sites, and displayed 48.1% sequence identity with the endothelial type, 43.1% with the neuronal type, and 99.3% with the inducible type from hepatocytes, and 99.9% with the inducible type from chondrocytes and adenocarcinoma.
|
7531687 |
1994 |